durvalumab,tremelimumab
astrazeneca,pfizer
['poseidon', 'nsclc', 'sclc', 'astrazeneca']
 showcased the results from the phase iii poseidon trial at the 2022. the exploratory analysis revealed long-term benefits that were sustained &amp; durable in frontline patients with metastatic nsclc. learn more: #esmo2022 #esmo #esmo22 
#DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the healthcare industry